No abstract
Eur Heart J Cardiovasc Pharmacother. 2026 Aug 26:pvag055. doi: 10.1093/ehjcvp/pvag055. Online ahead of print.
NO ABSTRACT
PMID:42647148 | DOI:10.1093/ehjcvp/pvag055
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
Scritto il 26/08/2026